CTLT Stock Overview
Develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Catalent, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$59.00 |
| 52 Week High | US$61.20 |
| 52 Week Low | US$36.74 |
| Beta | 1.16 |
| 11 Month Change | -1.96% |
| 3 Month Change | -0.44% |
| 1 Year Change | 48.99% |
| 33 Year Change | -54.47% |
| 5 Year Change | 10.86% |
| Change since IPO | 195.15% |
Recent News & Updates
Recent updates
Catalent, Inc.'s (NYSE:CTLT) Share Price Not Quite Adding Up
Aug 30
Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?
Jul 23Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy
Jun 25Catalent - Novo Holdings Merger: Attractive Spread
Feb 07Catalent: Debt Remains An Overhang
Dec 13Catalent Remains Overvalued
Oct 04Calculating The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)
Aug 14Catalent: Myriad Issues To Fix
Jul 31Catalent (NYSE:CTLT) Has A Somewhat Strained Balance Sheet
May 05A Look At The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)
Mar 27Why did Catalent stock soar today? Potential takeover by Danaher
Feb 06We Think Catalent (NYSE:CTLT) Is Taking Some Risk With Its Debt
Feb 01Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal
Jan 05An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued
Dec 27Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute
Dec 22Catalent falls after new short call from Glasshouse Research
Dec 08Catalent Q1 2023 Earnings Preview
Oct 31These 4 Measures Indicate That Catalent (NYSE:CTLT) Is Using Debt Extensively
Oct 26Catalent: Charting A Post-Covid Future
Oct 19Shareholder Returns
| CTLT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.3% | -3.8% | -1.0% |
| 1Y | 49.0% | 9.8% | 30.3% |
Return vs Industry: CTLT exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: CTLT exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| CTLT volatility | |
|---|---|
| CTLT Average Weekly Movement | 1.3% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CTLT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CTLT's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 16,900 | Alessandro Maselli | www.catalent.com |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Catalent, Inc. Fundamentals Summary
| CTLT fundamental statistics | |
|---|---|
| Market cap | US$10.69b |
| Earnings (TTM) | -US$413.00m |
| Revenue (TTM) | US$4.42b |
2.4x
P/S Ratio-25.9x
P/E RatioIs CTLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTLT income statement (TTM) | |
|---|---|
| Revenue | US$4.42b |
| Cost of Revenue | US$3.46b |
| Gross Profit | US$965.00m |
| Other Expenses | US$1.38b |
| Earnings | -US$413.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.28 |
| Gross Margin | 21.82% |
| Net Profit Margin | -9.34% |
| Debt/Equity Ratio | 130.0% |
How did CTLT perform over the long term?
See historical performance and comparison